Japan RA Registry
Our Japan RA registry is newly launched in 2015, focused on studying the unique aspects of rheumatoid arthritis in Japanese populations. The study is structured with four drug class arms:
- Methotrexate (500 patients)
- Anti-TNF biologics (500 patients)
- Non-TNF biologics (500 patients)
- JAK inhibitors (500 patients)
The Japan RA registry has been designed to closely mirror Corrona's US RA registry. The physician & patient questionnaires will therefore match all the traditional US Corrona data elements (DAS-28, ACR, CDAI, HAQ, EQ5D).
We are in discussion with over 42 sites from across Japan to join the Corrona Japan registry. The Principal Investigator of the Japan RA study is Professor Hisashi Yamanaka, of Tokyo Women’s Medical University Hospital.